According to research report the global in vitro toxicology testing market is projected to reach USD 8.74 billion by 2022 from USD 6.34 billion in 2017, at a CAGR of 6.6% during the forecast period.
Objectives of the Study
- To define, describe, and forecast the global market by product & service, toxicity endpoint & test, technology, method, industry, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World
- To profile key players and comprehensively analyze their core competencies in terms of key market developments, product portfolios, and financials
- To track and analyze competitive developments such as acquisitions, new product developments, partnerships, agreements, expansions, and collaborations in the global market
- To benchmark players within the global market using proprietary “Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Scope of the Report:
The research report categorizes the global market into the following segments and subsegments:
In vitro toxicology testing market, by Products & Services
- Assays
- Bacterial toxicity assays
- Enzyme toxicity assays
- Cell-based ELISA and western blots
- Receptor binding assays
- Tissue culture assays
- Other assays
- Services
- Reagents & labware
The major players in the global in vitro toxicology testing market include Cyprotex (An Evotec AG subsidiary, Germany), Covance (A Laboratory Corporations of America Holding’s subsidiary, US), Eurofins Scientific SE (Luxembourg), GE Healthcare (US), Thermo Fisher Scientific (US), SGS SA (Switzerland), Promega Corporation (US), Merck KGaA (Germany), Charles River Laboratories, Inc. (US), and Lonza Group Ltd. (Switzerland), among others.
